Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia
Neil E. Kay(Mayo Clinic), Chris L. Pashos(Oldham Council), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), David L. Grinblatt(NorthShore University HealthSystem), Mark Kozloff(Ingalls Memorial Hospital), Susan Lerner(Molecular Templates (United States)), Thomas J. Kipps(University of California San Diego), Thomas K. Street(Bristol-Myers Squibb (Switzerland)), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Arlene S. Swern, Ren Yu(Health Outcomes Solutions (United States)), Kristen Sullivan(Tufts University), Ian W. Flinn(Tennessee Oncology), Zeba M. Khan(Bristol-Myers Squibb (Switzerland)), Mark A. Weiss(Thomas Jefferson University)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k